Authors: Ribatti, D.; Crivellato, E.; Vacca, A.

Source: Current Medicinal Chemistry, Volume 19, Number 7, March 2012 , pp. 955-960(6)

Publisher: Bentham Science Publishers

Abstract:

The immune system regulates angiogenesis in cancer by means of pro- and anti-angiogenesis activities. In fact, both innate (macrophages, granulocytes, mast cells, dendritic cells, natural killer cells, and platelets) and adaptive (T and B lymphocytes) immune cells synthesize several pro- and anti-angiogenic mediators. Moreover, in pre-clinical models, a synergy has been observed between antiangiogenic molecules and immunotherapy. In this review article, we will focus on some angiogenenic and anti-angiogenic molecules properties of immune cells that may be utilized for a potential parmacological use as anti-angiogenic agents in cancer.

Keywords: Angiogenesis; anti-angiogenesis; adaptive immunity; inflammation; innate immunity; lymphocytes; macrophages; mast cells; neutrophils; platelets; tumor progression

Document Type: Research article

DOI: http://dx.doi.org/10.2174/092986712799320655

Publication date: 2012-03-01

More about this publication?

• Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Ribatti, D. ;  Crivellato, E. ;  Vacca, A.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers